Perspective Therapeutics, Inc. CATX
Set alert
1.04 USD -0.11 -9.57%
At close
1.10 +0.06 +5.77%
Pre-market · Nov 3, 4:17 AM ET
1.03 Day range 1.19
1.03 52-week range 6.16
- YTD
- -62.18%
- 1 year
- -60.00%
- Open
- 1.15
- Prev close
- 1.15
- Mkt cap
- 118.72M
- Vol
- 2.11M
- Avg vol
- 2.04M
- EPS
- -1.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.03
- High
- 1.19
- Forward P/E
- -2.91
- Beta
- 1.47
- Short ratio
- 4.69
- Inst. own
- 81.43%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.97
- 200-d avg
- 12.20
- 1y target
- 16.15
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 16.15 +1452.9% upside
Now 1.04
- Target (low)
- 6.00
- Target (mean)
- 16.15
- Target (high)
- 21.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.25994 | -0.27983 – -0.24 | 0.00 | 0.0% | 257.76K | +105.3% | 3 |
| Next quarter | -0.3003 | -0.3003 – -0.3003 | 0.00 | 0.0% | 151.33K | -53.4% | 1 |
| Current year | -0.83757 | -0.86271 – -0.80 | 0.00 | 0.0% | 1.35M | -5.6% | 3 |
| Next year | -1.33 | -1.61 – -0.99 | -0.83757 | -58.6% | 596.88K | -55.9% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 25, 2024 | B of A Securities | Downgrade | Buy | Neutral |
| Nov 22, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Oct 24, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Oct 24, 2024 | UBS | Initiated | — | Buy |
| Oct 11, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Oct 1, 2024 | Wedbush | Initiated | — | Outperform |
| Sep 25, 2024 | Truist Securities | Initiated | — | Buy |
| Sep 10, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Sep 6, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Sep 3, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Aug 16, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 13, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Jul 25, 2024 | B of A Securities | Initiated | — | Buy |
| Jun 25, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 20, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 18, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jun 18, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 14, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| May 16, 2024 | Jones Trading | Maintained | Buy | Buy |
| May 14, 2024 | RBC Capital | Initiated | — | Outperform |
| May 9, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Apr 9, 2024 | B. Riley Securities | Maintained | Buy | Buy |
| Apr 1, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 19, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jan 26, 2024 | B. Riley Securities | Initiated | — | Buy |
| Nov 15, 2023 | JonesTrading | Initiated | — | Buy |
| May 19, 2023 | Oppenheimer | Maintained | — | Outperform |